Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial - PubMed (original) (raw)
Clinical Trial
. 2010 Sep-Oct;31(5):457-65.
doi: 10.2164/jandrol.109.009597. Epub 2010 Feb 4.
Affiliations
- PMID: 20133964
- DOI: 10.2164/jandrol.109.009597
Clinical Trial
Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial
Christina Wang et al. J Androl. 2010 Sep-Oct.
Abstract
Currently available testosterone (T) injections in the United States are administered at 2-3 weekly intervals. Less frequent injections with favorable serum T pharmacokinetics would benefit hypogonadal men. The objective of this study is to assess the pharmacokinetics of long-acting testosterone undecanoate (TU) intramuscular (IM) injection in hypogonadal men. An unblinded, multicenter phase 3 clinical trial was conducted in 31 academic centers and contract research organizations. Males (130) more than 18 years of age with serum total T < 300 ng/dL were enrolled and received 750-mg injections of TU at weeks 0 and 4 and every 10 weeks thereafter for 9 injections over 84 weeks. The main outcome variables were serum total T, free T, dihydrotestosterone (DHT), estradiol (E(2)) levels, and safety parameters. After the first injection, patients maintained average trough T concentrations in the adult male range (300-1000 ng/dL or 10.4-34.7 nmol/L) before each injection and at multiple time points measured after the third and fourth injections. Serum free T, DHT, and E(2) levels and their ratios to serum T remained relatively consistent once steady state was attained. TU injections were generally well tolerated, with safety profiles similar to other T replacement. We conclude that hypogonadal patients treated for 84 weeks with a 750-mg IM injection of TU every 10 weeks demonstrated average concentrations of T, its metabolites (DHT and E(2)), and ratios--DHT:T and E(2):T--within the adult male reference range at all time points measured. TU injections would be an acceptable alternative to the currently available 2-3 weekly injectables.
Similar articles
- A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. Zhang GY, et al. J Androl. 1998 Nov-Dec;19(6):761-8. J Androl. 1998. PMID: 9876028 - Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F. Schubert M, et al. J Clin Endocrinol Metab. 2004 Nov;89(11):5429-34. doi: 10.1210/jc.2004-0897. J Clin Endocrinol Metab. 2004. PMID: 15531493 Clinical Trial. - Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S, Nieschlag E. von Eckardstein S, et al. J Androl. 2002 May-Jun;23(3):419-25. J Androl. 2002. PMID: 12002444 Clinical Trial. - More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren L, Nieschlag E. Saad F, et al. Asian J Androl. 2007 May;9(3):291-7. doi: 10.1111/j.1745-7262.2007.00275.x. Asian J Androl. 2007. PMID: 17486268 Review. - Testosterone undecanoate in the treatment of male hypogonadism.
Edelstein D, Basaria S. Edelstein D, et al. Expert Opin Pharmacother. 2010 Aug;11(12):2095-106. doi: 10.1517/14656566.2010.505920. Expert Opin Pharmacother. 2010. PMID: 20642374 Review.
Cited by
- Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males.
Pastuszak AW, Bush M, Curd L, Vijayan S, Priestley T, Xiang Q, Hu Y. Pastuszak AW, et al. J Clin Pharmacol. 2021 Dec;61(12):1618-1625. doi: 10.1002/jcph.1939. Epub 2021 Sep 12. J Clin Pharmacol. 2021. PMID: 34269421 Free PMC article. Clinical Trial. - A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial.
Pencina KM, Burnett AL, Storer TW, Guo W, Li Z, Kibel AS, Huang G, Blouin M, Berry DL, Basaria S, Bhasin S. Pencina KM, et al. J Clin Endocrinol Metab. 2021 Jul 13;106(8):2171-2186. doi: 10.1210/clinem/dgab361. J Clin Endocrinol Metab. 2021. PMID: 34019661 Free PMC article. Clinical Trial. - Accurate measurement of androgen after androgen esters: problems created by ex vivo esterase effects and LC-MS/MS interference.
Ceponis J, Swerdloff R, Leung A, Hull L, Bai F, Longstreth J, Dudley R, Danoff T, Wang C. Ceponis J, et al. Andrology. 2019 Jan;7(1):42-52. doi: 10.1111/andr.12554. Epub 2018 Oct 21. Andrology. 2019. PMID: 30345711 Free PMC article. - Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations.
Madsen MC, Heijer MD, Pees C, Biermasz NR, Bakker LEH. Madsen MC, et al. Endocr Connect. 2022 Jul 25;11(8):e220112. doi: 10.1530/EC-22-0112. Print 2022 Aug 1. Endocr Connect. 2022. PMID: 35904217 Free PMC article. Review. - Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis.
Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, Yarrow JF. Borst SE, et al. BMC Med. 2014 Nov 27;12:211. doi: 10.1186/s12916-014-0211-5. BMC Med. 2014. PMID: 25428524 Free PMC article. Review.